Retatrutide (LY-3437943) is a triple hormone receptor agonist of GLP-1, GIP, and GCGR receptors.

Retatrutide, currently in development for obesity, type 2 diabetes (T2D), and non-alcoholic fatty liver disease (NAFLD), is of special interest due to addressing the need for improved efficacy within the obesity space.